| Bioactivity | Kynostatin 272 (KNI 272; NSC 651714) is a potent HIV protease inhibitor. Kynostatin 272 inhibits the activity of the HIV protease by simulating the substrate transition state of the HIV protease, thus preventing a key step in the replication of the HIV virus. Kynostatin 272 provides an important research foundation for the development of drugs for HIV and AIDS[1][2]. |
| CAS | 147318-81-8 |
| Formula | C33H41N5O6S2 |
| Molar Mass | 667.84 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kimura T, et al. Rigid backbone moiety of KNI-272, a highly selective HIV protease inhibitor: methanol, acetone and dimethylsulfoxide solvated forms of 3-[3-benzyl-2-hydroxy-9-(isoquinolin-5-yloxy)-6-methylsulfanylmethyl-5, 8-dioxo-4, 7-diazanonanoyl]-N-tert-butyl-1, 3-thiazolidine-4-carboxamide[J]. Acta Crystallographica Section B: Structural Science, 2004, 60(4): 433-437. [2]. Freedberg D I, et al. Flexibility and function in HIV protease: Dynamics of the HIV-1 protease bound to the asymmetric inhibitor kynostatin 272 (KNI-272)[J]. Journal of the American Chemical Society, 1998, 120(31): 7916-7923. |
Kynostatin 272
CAS: 147318-81-8 F: C33H41N5O6S2 W: 667.84
Kynostatin 272 (KNI 272; NSC 651714) is a potent HIV protease inhibitor. Kynostatin 272 inhibits the activity of the HIV
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.